CS-003 Free base structure
|
Common Name | CS-003 Free base | ||
|---|---|---|---|---|
| CAS Number | 191672-52-3 | Molecular Weight | 673.65 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C34H38Cl2N2O6S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of CS-003 Free baseCS-003 Free base (CS-003), a triple tachykinin receptor antagonist, shows high affinities for human (Neurokinin) NK1, NK2 and NK3 receptors with Ki values of 2.3 nM, 0.54 nM and 0.74 nM, respectively. CS-003 Free base (CS-003) has therapeutic efficacy on respiratory diseases associated with neurokinins. |
| Name | CS-003 Free base |
|---|
| Description | CS-003 Free base (CS-003), a triple tachykinin receptor antagonist, shows high affinities for human (Neurokinin) NK1, NK2 and NK3 receptors with Ki values of 2.3 nM, 0.54 nM and 0.74 nM, respectively. CS-003 Free base (CS-003) has therapeutic efficacy on respiratory diseases associated with neurokinins. |
|---|---|
| Related Catalog | |
| Target |
NK1:2.3 nM (Ki) NK2:0.54 nM (Ki) NK3:0.74 nM (Ki) |
| In Vitro | CS-003 (0.01-10 μM; 24 hours) inhibits NK1, NK2 or NK3 induced inositol phosphate formation in a concentration-dependent manner with pA2 values of 8.7, 9.4 and 9.5 μM, respectively[1]. |
| In Vivo | CS-003 (intravenous injection; 0.01-3.0 mg/kg; 5 min before neurokinin A/B/C injection) inhibits substance P-induced tracheal vascular hyperpermeability, neurokinin A- and neurokinin B-induced bronchoconstriction with ID50 values of 0.13, 0.040 and 0.063 mg/kg, respectively[1]. |
| References |
| Molecular Formula | C34H38Cl2N2O6S |
|---|---|
| Molecular Weight | 673.65 |
| InChIKey | RWSBBXFLRGQFQP-KHIDOSKGSA-N |
| SMILES | COc1cc(C(=O)N2CCOC(CCN3CCC4(CC3)c3ccccc3CS4=O)(c3ccc(Cl)c(Cl)c3)C2)cc(OC)c1OC |